Corona Remedies Limited (NSE: CORONA) and Marksans Pharma Ltd. (NSE: MARKSANS) are both listed in the Pharmaceuticals industry. Corona Remedies has a market capitalisation of ₹13,278 Cr and Marksans Pharma ₹14,152 Cr, as of 9 Nov 2026. Their P/E ratios are 71.7 and 33.9 respectively. Return on equity is 24.79% for Corona Remedies and 25.45% for Marksans Pharma.
| Metric | Corona Remedies | Marksans Pharma |
|---|---|---|
| NSE Symbol | CORONA | MARKSANS |
| BSE Code | 544644 | 524404 |
| Share Price | ₹2,545.70 | ₹309.00 |
| Market Cap | ₹13,278 Cr | ₹14,152 Cr |
| P/E Ratio | 71.7 | 33.9 |
| Return on Equity | 24.79% | 25.45% |
| Return on Assets | 14.99% | 8.85% |
| Dividend Yield | 0.46% | 0.29% |
| Beta (1Y) | 0.24 | 0.7 |
| 1-Year Price Change | — | +62.3% |
| 3-Month Price Change | +22.3% | +13.8% |
| 52-Week Range | ₹1,336.60 – ₹2,719.30 | ₹155.00 – ₹350.95 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹441 Cr | ₹940 Cr |
| Quarterly Net Profit | ₹60 Cr | ₹144 Cr |
| Net Margin | 13.7% | 15.3% |
| EPS (Basic, Quarter) | ₹9.86 | ₹3.12 |
| Results Basis | consolidated | consolidated |
| Headquarters | Ahmedabad, Gujarat | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women’s healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeuti…
Marksans Pharma has a market capitalisation of ₹14,152 Cr, against ₹13,278 Cr for Corona Remedies as of 9 Nov 2026, so the two are about the same size by market cap.
Corona Remedies has a P/E of 71.7 and Marksans Pharma a P/E of 33.9 as of 9 Nov 2026.
Corona Remedies has a return on equity of 24.79% and Marksans Pharma 25.45%.
Corona Remedies reported revenue of ₹441 Cr and net profit of ₹60 Cr for Q2 FY27. Marksans Pharma reported revenue of ₹940 Cr and net profit of ₹144 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Pharmaceuticals on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.